Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932732 · ClinicalTrials.gov registry record · Phase 4
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
A Phase 4 study of Cutis Laxa Facialis and Xeroderma, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT05932732 is a Phase 4 study of Cutis Laxa Facialis and Xeroderma that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 27 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05932732, a Phase 4 study of Cutis Laxa Facialis and Xeroderma, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before and after three (3) HF treatments, in 6 patient cohorts, each cohort defined by FST I-VI.
Conditions Studied
Interventions
- DEVICE HydraFacial Syndeo System
- DRUG ReGen-GF
- DEVICE HydraFacial Elite MD System
Study Locations (2)
Texas
- Austin Institute for Clinical Research, Inc. - Houston
- Austin Institute for Clinical Research, Inc. - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2024-10-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05932732
The ClinicalTrials.gov registry entry for NCT05932732 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Austin Institute for Clinical Research, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutis Laxa Facialis appearing as the primary indexed condition, and to 3 interventions - of which HydraFacial Syndeo System is the first listed.
NCT05932732 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05932732 about?
NCT05932732 is a clinical study titled "Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.". This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before an...
What is the current status of trial NCT05932732?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2023-11-20. Estimated completion is 2024-10-09.
What conditions does trial NCT05932732 study?
This clinical trial studies the following conditions: Cutis Laxa Facialis, Xeroderma.
What interventions are being tested in trial NCT05932732?
The interventions under investigation include: HydraFacial Syndeo System (DEVICE), ReGen-GF (DRUG), HydraFacial Elite MD System (DEVICE).
Who is sponsoring clinical trial NCT05932732?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05932732 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.